---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-005442"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2026-08-12T11:31:19+00:00"
generated_at: "2026-08-12T11:35:07.715931+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Arbutus Q2 net loss $5.1M; receives $178M Moderna payment, plans $230M buyback

## Summary
- Q2 revenue fell to $1.0M from $10.7M YoY; net loss of $5.1M ($0.03/share) vs net income of $2.5M in 2025.
- Received $178.4M from Moderna settlement in July; owns ~16% of Genevant and expects a dividend.
- Board authorized up to $230M share repurchase program, may include tender offer, starting Q3 2026.
- Filed international patent lawsuits against Pfizer and BioNTech across 21 countries for LNP technology.
- FDA granted Fast Track for imdusiran; alignment on Phase 2b design for chronic hepatitis B.

## SEC filing metadata
- accession: 0001171843-26-005442
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2026-08-12T11:31:19+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184326005442/0001171843-26-005442-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184326005442/f8k_081226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-005442
- JSON: https://secwatch.observer/filing/0001171843-26-005442.json
- Plain text: https://secwatch.observer/filing/0001171843-26-005442.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.